Canada Life’s Kymera Therapeutics KYMR Stock Holding History

Canada Life’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$608K	Hold	5,310	–	–	﹤0.01%	1467
2026 Q1	$445K	Buy	5,310 +1,379	+35%	+$109K	﹤0.01%	1517
2025 Q4	$306K	Sell	3,931 -6,560	-63%	-$443K	﹤0.01%	1573
2025 Q3	$614K	Hold	10,491	–	–	﹤0.01%	1564
2025 Q2	$458K	Hold	10,491	–	–	﹤0.01%	1625
2025 Q1	$288K	Hold	10,491	–	–	﹤0.01%	1691
2024 Q4	$422K	Hold	10,491	–	–	﹤0.01%	1669
2024 Q3	$497K	Hold	10,491	–	–	﹤0.01%	1671
2024 Q2	$313K	Buy	10,491 +6,560	+167%	+$227K	﹤0.01%	1766
2024 Q1	$158K	Hold	3,931	–	–	﹤0.01%	1865
2023 Q4	$99K	Buy	3,931 +2,287	+139%	+$40.9K	﹤0.01%	1950
2023 Q3	$23K	Hold	1,644	–	–	﹤0.01%	2108
2023 Q2	$38K	Hold	1,644	–	–	﹤0.01%	2035
2023 Q1	$49K	Hold	1,644	–	–	﹤0.01%	2071
2022 Q4	$41K	Hold	1,644	–	–	﹤0.01%	2114
2022 Q3	$36K	Hold	1,644	–	–	﹤0.01%	2160
2022 Q2	$32K	Hold	1,644	–	–	﹤0.01%	2159
2022 Q1	$74K	Buy	1,644 +392	+31%	+$16.6K	﹤0.01%	2074
2021 Q4	$79K	Buy	1,252 +507	+68%	+$29.5K	﹤0.01%	2063
2021 Q3	$44K	Hold	745	–	–	﹤0.01%	2266
2021 Q2	$36K	Hold	745	–	–	﹤0.01%	2357
2021 Q1	$29K	Hold	745	–	–	﹤0.01%	2448
2020 Q4	$46K	Buy	+745	New	+$36.3K	﹤0.01%	2307

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Canada Life's KYMR Position: Q2 2026 in Review

Canada Life held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 5,310 shares worth $608K. The position accounts for ﹤0.01% of the portfolio, ranked #1467.

Canada Life first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. The position peaked at $614K in Q3 2025. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Canada Life held 5,310 shares of Kymera Therapeutics worth $608K as of Q2 2026.
Canada Life left its Kymera Therapeutics share count unchanged in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of Canada Life's portfolio in Q2 2026, its #1467 holding.
Canada Life first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
Canada Life's Kymera Therapeutics position peaked at $614K in Q3 2025.
277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.